4-(6-methoxynaphthalen-2-yl)-4-oxo-2-butenoic-acid and Glioma

Diagnostic value of 3,4-dihydroxy-6-[. Patients with a proven HGG (WHO grade III and IV) were referred to the multidisciplinary neuro-oncology board (MNOB) during their follow-up after initial standard of care treatment and when MRI findings were not fully conclusive. Each case was discussed in 2 steps. For step 1, a diagnosis and a management proposal were made only based on the clinical and the MRI data. For step 2, the same process was repeated taking the [. 107 patients underwent a total of 138 MNOB assessments. The proposed diagnosis changed between step 1 and step 2 in 37 cases (26.8%) and the proposed management changed in 31 cases (22.5%). When the management did not change, the confidence in the MNOB final decision was increased in 87 cases (81.3%). Step 1 had a sensitivity, specificity and accuracy of 83%, 58% and 66% and step 2, 86%, 64% and 71% respectively.. [

Topics: Brain Neoplasms; Dihydroxyphenylalanine; Glioma; Humans; Neoplasm Recurrence, Local; Positron-Emission Tomography; Prospective Studies; Radiopharmaceuticals; Sensitivity and Specificity